Tr1x Inc. announced a $75 million series A financing to advance universal allogeneic regulatory T (Treg) and chimeric antigen receptor (CAR)-Treg cell therapies into the clinic to treat autoimmune and inflammatory diseases.
Inhibiting the aggregation process of Aβ42 is one of the main objectives in the development of therapies for Alzheimer’s disease, but the heterogeneous nature of the neurotoxic oligomers poses a significant challenge. Researchers from the Universita degli Studi di Firenze presented the preclinical evaluation of DesAb-O, a single-domain antibody targeting Aβ42 oligomers.
The combination of chemotherapy (CT) and photodynamic therapy (PDT), which combines light and a photosensitizing agents, is increasingly being used to enhance the efficacy of cancer treatments.
Angiopoietin-like 4 (ANGPTL4) is a glycosylated and secreted protein that functions as a regulator of cell metabolism and angiogenesis, and which has been shown to play a critical role in tumorigenesis.
Researchers from China have elucidated the prognostic role of aberrant expression of RNA binding motif protein, X chromosome (RBMX) in several cancer types using samples from cancer patients.
The Cleveland Clinic Foundation has described 3-β-hydroxysteroid dehydrogenase/δ5-->4-isomerase type 1 (3β-HSD I) inhibitors reported to be useful for the treatment of cancer.
Researchers at Guangzhou Salustier Biosciences Co. Ltd. and Jinan University (Guangdong) have identified selenium-containing heterocyclic compounds acting as GTPase KRAS (G12D mutant) inhibitors reported to be useful for the treatment of cancer.
RSS
